Open-Label, Multicenter Study on the Safety, Tolerability, and Efficacy of Simulect in Pediatric Renal Transplant Recipients Receiving Triple Therapy With Cyclosporin, Mycophenolate, and Corticosteroids

Basiliximab is a monoclonal antibody directed to theinterleukin-2 receptor. Several studies have demonstrated both its efficacy and safety. Even with the use of polyclonal antibodies in renal pediatric transplant recipients, the local incidence of steroid-resistant rejections has been close to 10% of the total incidence of acute rejection episodes (AREs). An open, multicenter prospective study was performed to assess the safety tolerability, and efficacy of induction with basiliximab in renal pediatric transplant patients receiving cyclosporine, mycophenolate, and steroids. Eighteen patients (8 boys) of mean age 11.9 ± 4.5 years and body weight 32 ± 15 kg received cadaveric (n = 7) or living (n = 11) donor grafts. Simulect was administered on days 0 and 4. Efficacy was assessed by the incidence of biopsy-proven acute rejection (BPAR). Safety assessment consisted of a description of the adverse events (AEs). Six BPAR (Banff I and II) occurred in 5, (27.7%) children all of which were steroid responsive. Creatinine levels at day 7 and months 3, 6, and 12 were 1.6 ± 1.5 mg/dL, 1.0 ± 0.4 mg/dL, 1.0 ± 0.5 mg/dL, and 1.0 ± 0.4 mg/dL, respectively. Schwartz calculation at 12 months was 71 ± 15 mL/1.73 m 2 AEs were hypertension (12), anemia (9), abdominal pain (8), metabolic acidosis (8), nausea (7), diarrhea (2), gingival hypertrophy (2), hirsutism (2), lymphocele (2), and infections (15). No deaths, graft losses, PTLDs, or malignancies were observed. No steroid-resistant AREs, were observed in this pediatric group using basiliximab. The Schwartz calculation at 12 months was 71 ± 15 mL/min/1.73 m 2.